<DOC>
	<DOC>NCT01032187</DOC>
	<brief_summary>The purpose of this study is to determine if amphotericin B is effective against visceral leishmaniasis in Brazilian children. Amphotericin B will be compared to meglumine antimoniate which is the current approved drug used for this disease in Brazil.</brief_summary>
	<brief_title>Amphotericin B to Treat Visceral Leishmaniasis in Brazilian Children</brief_title>
	<detailed_description />
	<mesh_term>Leishmaniasis</mesh_term>
	<mesh_term>Leishmaniasis, Visceral</mesh_term>
	<mesh_term>Amphotericin B</mesh_term>
	<mesh_term>Liposomal amphotericin B</mesh_term>
	<mesh_term>Amphotericin B, deoxycholate drug combination</mesh_term>
	<mesh_term>Meglumine antimoniate</mesh_term>
	<mesh_term>Deoxycholic Acid</mesh_term>
	<criteria>Clinical symptoms of visceral leishmaniasis: fever plus hepatomegaly or splenomegaly Diagnosis of visceral leishmaniasis confirmed through parasite visualization in bone marrow smears or positive serology (indirect immunofluorescent antibody test or rK39 rapid test)or positive kDNA PCR test Any of the following laboratory findings Total serum bilirubin higher than 2,5 mg/dL Serum SGOT higher than 5 times the upper normal level Serum SGPT higher than 5 times the upper normal level Prothrombin time concentration lower than 70% Abnormal serum creatinine Any of the following signs or symptoms Generalized edema Severe malnutrition Systemic inflammatory response syndrome Any of the following conditions HIV infection/disease Diabetes Corticoid or immunosuppressive drugs use Symptomatic heart diseases Chronic hepatic or renal diseases Lupus erythematosus</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>Visceral leishmaniasis</keyword>
	<keyword>Amphotericin B deoxycholate</keyword>
	<keyword>Meglumine antimoniate</keyword>
	<keyword>Children</keyword>
	<keyword>Brazil</keyword>
</DOC>